Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas.
In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies.
It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Jeffrey F. Eisenberg Esq. |
Contact Details
Address: 945 Concord St. Framingham, Massachusetts 01701 United States | |
| Phone | 781-778-7720 |
| Website | xeneticbio.com |
Stock Details
| Ticker Symbol | XBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534525 |
| CUSIP Number | 984015503 |
| ISIN Number | US9840156023 |
| Employer ID | 45-2952962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey F. Eisenberg Esq. | Chief Executive Officer, President and Director |
| James F. Parslow | Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
| Dr. Curtis A. Lockshin | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 12, 2024 | 8-K | Current Report |
| Dec 8, 2023 | 8-K | Current Report |
| Nov 13, 2023 | ARS | Filing |
| Nov 13, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Sep 18, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |